The latent membrane protein 2A (LMP2A) of Epstein -Barr virus (EBV) is an important mediator of viral latency in infected Blymphocytes. LMP2A inhibits B-cell receptor (BCR) signaling in vitro and allows for the survival of BCR-negative B cells in vivo. In this study, we compared gene transcription in BCR-activated B cells from non-transgenic and LMP2A Tg6 transgenic mice. We found that the transcriptional induction and down-regulation of many genes that normally occurs in B cells following BCR activation did not occur in B cells from LMP2A Tg6 transgenic mice. Furthermore, LMP2A induced the expression of various transcription factors and genes associated with DNA/RNA metabolism, which may allow for the altered transcriptional regulation observed in BCR-activated B cells from LMP2A Tg6 mice. These results suggest that LMP2A may inhibit the downstream effects of BCR signaling by directly or indirectly altering gene transcription to ensure EBV persistence in infected B cells.
Introduction
Epstein-Barr virus (EBV) infection is associated with the development of a variety of malignancies of both lymphoid and epithelial origin, including Hodgkin's lymphoma, Burkitt's lymphoma, nasopharyngeal carcinoma, and various lymphoproliferative disorders arising in immunocompromised individuals (Kieff and Rickinson, 2001; Thorley-Lawson, 2001 ). Primary EBV infection usually occurs during childhood and, following an initial, self-limiting infection, EBV establishes a lifelong latent infection in B lymphocytes. Viral gene expression in latently infected B cells is limited to transcription of EBV nuclear antigen 1 (EBNA1), latent membrane protein 2A (LMP2A), EBV-encoded RNAs (EBERs), and BamHI-A-rightward transcripts (BARTS) (Chen et al., 1995 (Chen et al., , 1999 Qu and Rowe, 1992; Thorley-Lawson, 2001; Tierney et al., 1994) . The consistent detection of LMP2A transcripts in both tumor cells and latently infected B cells in vivo suggests that LMP2A plays an important role in viral persistence and in the development of EBV-associated diseases.
In latently infected lymphocytes, LMP2A resides in small glycolipid-enriched microdomains in the plasma membrane, where it appears to mimic an activated B-cell receptor (BCR) (Dykstra et al., 2001; Longnecker, 2000) . BCR activation in LMP2A-expressing cells fails to induce calcium mobilization and activation of the downstream signaling molecules Lyn, Syk, phosphatidylinositol 3-kinase (PI3-K), phospholipase C-g2 (PLCg2), Vav, Shc, and mitogen-activated protein kinase (MAPK) (Miller et al., 1995 (Miller et al., , 1993 . Instead, these molecules are constitutively phosphorylated in the presence of LMP2A. The aminoterminal cytoplasmic domain of LMP2A contains eight tyrosines (Burkhardt et al., 1992; Miller et al., 1995) . Phosphotyrosines at positions 74 and 85 (an immunoreceptor tyrosine-based motif (ITAM)) in LMP2A bind the protein tyrosine kinase Syk while tyrosine 112 binds the Src family kinase Lyn. Mutational analyses indicate that all three residues are essential for the LMP2A-mediated block in BCR signaling (Fruehling and Longnecker, 1997; Fruehling et al., 1998) . It is likely that LMP2A provides a constitutive positive signal and, by sequestering Lyn and Syk, prevents normal BCR signal transduction. By inhib-iting B-cell activation, LMP2A may prevent the induction of lytic EBV replication and subsequent immune recognition of infected cells.
Mice transgenic for LMP2A have demonstrated that this protein is able to interfere with normal B-cell development, allowing BCR-negative cells to exit the bone marrow and colonize peripheral organs (Caldwell et al., 1998) . Two types of LMP2A transgenic lines have been described. The TgE line has significantly reduced numbers of CD19+ B cells in the bone marrow and spleen and a significant percentage of these B cells do not express surface immunoglobulin (Ig). Furthermore, bone marrow B cells from these mice undergo Ig light chain, but not heavy chain, gene rearrangement (Caldwell et al., 1998 . This indicates that LMP2A signaling can bypass the requirement for Ig recombination and allow BCR-negative cells, which would normally undergo apoptosis, to colonize peripheral lymphoid organs. The LMP2A-mediated effects on B-cell development and survival in vivo have been shown to require the ITAM (Syk binding) (Merchant et al., 2000) . In addition, studies utilizing mice deficient for the downstream B-cell signaling components BLNK (SLP-65) or Bruton's tyrosine kinase (Btk) have demonstrated that LMP2A utilizes these molecules for its effects on B-cell development Fig. 1 . Increased tyrosine phosphorylation in purified B cells following BCR activation. B cells from wild-type (WT) and LMP2A Tg6 transgenic mice were treated with goat anti-mouse Ig for 5 min to activate the BCR. Cell lysates were extracted from 5 Â 10 6 cells and equivalent amounts of protein were utilized for Western blot analysis with anti-phosphotyrosine antibodies. Tyrosine phosphorylation was similarly induced in both wildtype and LMP2A Tg6 B cells following BCR activation. Fig. 2 . Comparison of gene expression profiles in wild-type and LMP2A Tg6 B cells. The average differences in hybridization intensities for genes in each sample were plotted against each other in graphs to demonstrate the overall similarities and differences in gene expression in unstimulated and BCR-activated B cells from wild-type (WT) and LMP2A Tg6 transgenic mice. Plotted against each other are the average differences in gene expression in (A) unstimulated (unst) and BCR-activated (+Ig) wildtype B cells, (B) unstimulated and BCR-activated B cells from LMP2A Tg6 transgenic mice, (C) BCR-activated B cells from wild-type and Tg6 transgenic mice, and (D) unstimulated B cells from wild-type and Tg6 transgenic mice. and survival (Engels et al., 2001; Merchant and Longnecker, 2001 ).
The LMP2A Tg6 transgenic line displays lower levels of LMP2A mRNA expression and a more subtle phenotype in a wild-type background, demonstrating a slight reduction in the total number of mature, BCR-positive B cells. However, crosses between LMP2A Tg6 transgenic mice and mice deficient for recombinase-activating gene-1 (RAG-1) result in the production of BCR-negative cells in peripheral lymphoid organs similar to TgE LMP2A mice . This suggests that the extent to which LMP2A can bypass normal B-cell developmental checkpoints correlates with the transgene expression levels; however, the presence of BCR-positive cells in the LMP2A Tg6 line provides a unique model in which to specifically study the effects of LMP2A on BCR signaling in vivo.
Through the use of DNA microarray technology, many transcriptional abnormalities have been identified in B cells from the LMP2A TgE transgenic line. In these cells, LMP2A appears to globally repress the expression of genes associated with normal B-cell development as well as transcription factors that regulate expression of those genes (Portis and Longnecker, 2003) . In this study, we have analyzed gene expression in splenic B cells from the LMP2A Tg6 transgenic line following BCR activation. Our studies indicate that, compared to gene expression in activated B cells from non-transgenic mice, LMP2A interferes with the transcriptional induction and down-regulation of many genes that normally occurs upon BCR activation.
Results

BCR activation of B cells from wild-type and LMP2A Tg6 transgenic mice
To determine the effects of LMP2A on BCR signaling in primary B cells, we utilized DNA microarray analysis to directly compare gene transcription in unstimulated and BCR-activated B cells from LMP2A Tg6 transgenic mice and non-transgenic littermates. Activation of B cells was first verified by measuring phosphotyrosine activity following treatment of cells with anti-mouse Ig to stimulate BCR signaling. Fig. 1 indicates that BCR activation of purified B cells from both wild-type (WT) and LMP2A Tg6 mice resulted in increased tyrosine phosphorylation (compare 
(continued on next page) lanes 2 and 4 to lanes 1 and 3). Interestingly, phosphotyrosine levels were induced similarly upon BCR activation in both wild-type and LMP2A Tg6 B cells. In contrast to human B cell lines, which demonstrate constitutive tyrosine phosphorylation in the presence of LMP2A, B cells from LMP2A Tg6 transgenic mice do not exhibit constitutive phosphotyrosine activity. This is most likely due to lower basal levels of LMP2A expression in primary murine Tg6 B cells.
Overall analysis of gene expression following BCR activation
Total RNA was isolated from unstimulated and BCRactivated B cells from wild-type and LMP2A Tg6 transgenic mice and utilized for microarray analyses. Gene expression was analyzed after 5 h of BCR activation to detect both early and late mRNA induction as well as mRNA down-regulation or degradation that may result from BCR signaling. RNA expression levels for genes contained in Affymetrix microarrays were measured by hybridization intensity and the relative abundance of each gene was expressed as the ''average difference''. This value represents the difference in fluorescence intensity for RNAs hybridized to matched versus mismatched oligos. A complete listing of the microarray results is available at http://bugs.mimnet.northwestern. edu/mimweb/microarray.htm. The average differences in hybridization intensities for genes in each sample were plotted in graphs to demonstrate the overall similarities and differences in gene expression (Fig. 2) . Fig. 2A demonstrates a representative comparison of gene expression in B cells from wild-type (WT) mice, unstimulated (unst) versus BCRactivated (+Ig). Many differences in gene expression (twofold or higher) were induced upon BCR stimulation and are indicated as outliers closer to the two axes in the scatter plot ( Fig. 2A) . Of over 10,000 unique transcripts identified by the microarrays, 158 genes were induced and 127 genes were down-regulated following BCR activation. In contrast, BCR activation of B cells from LMP2A Tg6 transgenic mice did not appear to induce significant changes in gene transcription when compared to expression in unstimulated cells (Fig.  2B) . In BCR-activated B cells from LMP2A Tg6 mice, expression of 41 genes was induced and 73 genes were down-regulated. A comparison of gene expression following BCR activation in B cells from wild-type versus LMP2A Tg6 transgenic mice revealed many significant differences in gene transcription when compared to untreated B cells from the same mice (compare Figs. 2C and 2D) . In fact, the scatter plot showing gene expression in unstimulated B cells from wild-type versus LMP2A Tg6 mice (Fig. 2D) indicates that these two groups are transcriptionally similar before BCR activation. These results suggest that LMP2A alters the normal regulation of gene transcription that occurs following BCR activation.
Differential changes in gene expression following BCR activation
The changes in gene expression induced upon BCR activation were compared between B cells from wild-type and LMP2A Tg6 transgenic mice. Of the genes that were altered upon BCR activation, expression of 61 genes was statistically different in BCR-activated B cells from wild-type versus LMP2A Tg6 transgenic mice. Of the 61 genes, 49 (80%) were up-regulated and 12 (20%) were down-regulated upon BCR stimulation when compared to B cells from LMP2A Tg6 mice (Fig. 3A) . Expression of 45 genes was statistically different in BCR-activated B cells from LMP2A Tg6 transgenic mice versus wild-type mice. Of these, 20 (44%) were up-regulated and 25 (56%) were down-regulated upon BCR stimulation when compared to B cells from wildtype mice (Fig. 3A) . The large difference in the percentage of genes increased in B cells from wild-type versus LMP2ATg6 mice following BCR activation, together with differences indicated in the scatter plots (Fig. 2) , further suggests that LMP2A represses the transcription of many genes that should normally be induced upon BCR activation. Differentially expressed genes in BCR-stimulated B cells from non-transgenic and LMP2A Tg6 transgenic mice were placed into categories based on protein function. Those genes with unknown function or whose category placement was unclear were designated as other/unknown. Fig. 3B indicates the relative percentage of genes in each category whose expression was differentially increased (bars 1 and 2) or decreased (bars 3 and 4) upon BCR activation of B cells from wild-type (bars 1 and 3) versus LMP2A Tg6 transgenic mice (bars 2 and 4).
Several categories of genes appeared to be specifically altered by LMP2A following BCR activation. In general, many genes involved in protein transport and sorting and those involved in cell -cell interactions were increased in BCR-activated B cells from wild-type mice, but decreased in B cells from LMP2A Tg6 transgenic mice (Fig. 3B , compare bars 1 and 4). Similarly, a larger percentage of genes involved in inflammation and immunity were increased in BCRactivated B cells from wild-type mice compared to those from LMP2A Tg6 mice (Fig. 3B, compare bars 1 and 2) . In contrast, a larger percentage of genes encoding transcription factors, involved in DNA/RNA metabolism, and associated with cell cycle/apoptosis were increased in BCR-activated B cells from LMP2A Tg6 transgenic mice when compared to wild-type mice (Fig. 3B, compare bars 1 and 2) .
Expression of genes encoding signaling proteins, enzymes and those involved in protein metabolism, and those associated with cell cycle/apoptosis was decreased more significantly in B cells from wild-type versus LMP2A Tg6 transgenic mice (Fig. 3B , compare bars 3 and 4). Expression of genes encoding cytoskeletal proteins was only affected in BCR-activated B cells from LMP2A Tg6 transgenic mice, both positively and negatively (Fig.  3B, bars 2 and 4) . Taken together, these results suggest that LMP2A prevents the induction of genes involved in protein transport and sorting, cell -cell interactions, and inflammation and immunity following BCR activation. Furthermore, LMP2A prevents the down-regulation of genes encoding signaling proteins, those involved in cell cycle/apoptosis, and those encoding enzymes and involved in protein metabolism following BCR activation. LMP2A may be able to accomplish this by altering the expression of genes encoding transcription factors and regulators of DNA/RNA metabolism. Table 1 lists the specific genes whose expression was increased upon BCR activation of B cells from wild-type mice, but not LMP2A Tg6 transgenic mice (first 49 genes), or decreased in B cells from LMP2A Tg6 mice, but not wild-type mice (last 25 genes). Shown is the average fold change in gene expression from two separate, identical experiments. Those genes with an average difference in expression of twofold or greater, probability values of less than 0.05, and Affymetrix calls other than no change (NC), were considered significant. The Affymetrix call, based upon statistical significance within probes sets, is listed, along with the functional categories in which the genes were placed for Fig. 3 . As indicated previously and shown in Table 1 , expression of 49 genes was increased in BCRactivated B cells from wild-type mice; however, no change was detected in their expression in BCR-activated B cells from LMP2A Tg6 transgenic mice. Genes that were only induced upon BCR activation of B cells from wild-type mice and possibly important for B-cell function included genes involved in cell -cell interactions (Adam2, Lamb2, Ncam2, Ndph, Nrp, S100a1), inflammation and immunity (Cd160, IgA, IgH, Klrg1, Mbp, Rfxank, Sftpd, Slpi), and protein transport and sorting (Anxa7, Bsn, Cct6a, Freq, Slc15, Slc2). BCR activation of B cells from wild-type mice also resulted in increased expression of various signaling molecules that were not induced in B cells from LMP2A Tg6 mice, including Adcyap1, Esp, Grb7, Madh3, Ptprd, Rgs9, and Ubce7ip3. In contrast, activation of B cells from LMP2A Tg6 mice led to reduced expression of an important cell cycle checkpoint gene, Bub3, as well as genes encoding proteins involved in cell -cell interactions (Fbn1, Jcam3, Sdc1), inflammation and immunity (MHC class II, Ig, Il-4, ScFv, Tnfrsf18), and protein transport and sorting (Atp7a, Hspa8, Trpm7). Expression of these genes was either unchanged or increased in BCR-activated B cells from non-transgenic mice (Table 1) . Table 2 lists the specific genes whose expression was decreased upon BCR activation of B cells from wild-type, but not LMP2A Tg6 transgenic mice (first 12 genes) or increased in B cells from LMP2A Tg6 mice, but not wildtype mice (last 20 genes). BCR activation of B cells from wild-type mice resulted in decreased expression genes encoding proteins involved in cell cycle/apoptosis (Pdcd2, Rnf7), enzymes and those involved in protein metabolism (Cmas, Dhcr7, Hsd17b4, Ptdss2), and inflammation and immunity (Klrb1a, Tgfbr1, Vpreb3). Interestingly, BCR activation of B cells from LMP2A Tg6 mice resulted in increased expression of genes encoding proteins involved in cell cycle/apoptosis (Cdkn2b, Rck1), DNA/RNA metabolism (Rpl19, Zfp179, Zfp312), and various transcription factors (Nfib, Nr5a2, Sh2d2a, Smaf1, Sox18) . Again, expression of these genes was either unchanged or decreased in BCR-activated B cells from non-transgenic mice (Table 2) .
Genes differentially expressed upon BCR activation
Taken together, our data indicate that LMP2A prevents the transcriptional induction of many genes following BCR activation, while inhibiting the down-regulation of other genes involved in normal B-cell activation. Furthermore, LMP2A induces the expression of various transcription factors and genes associated with DNA/RNA metabolism, which may allow for the altered transcriptional regulation observed in BCR-activated B cells from LMP2A Tg6 mice.
Discussion
The identification of altered transcriptional regulation following BCR activation of B cells from LMP2A Tg6 mice is similar to our recent observation that LMP2A globally represses gene transcription necessary for proper B-cell development when expressed during B lymphopoiesis in the LMP2A TgE transgenic line (Portis and Longnecker, 2003) . In these mice, signaling through the pre-BCR appears to be inhibited or bypassed by LMP2A as indicated by the presence of improperly developed, BCR-negative B cells in peripheral lymphoid organs. The use of LMP2A Tg6 mice, in which B cells express a BCR despite LMP2A expression, provides an alternative model in which to more specifically study the effects of LMP2A on BCR signaling in vivo.
It has been clearly demonstrated using human cell lines in vitro that LMP2A interferes with signaling through the BCR. IgM crosslinking of B cells expressing LMP2A fails to activate calcium mobilization and phosphorylation of downstream BCR signaling components (Miller et al., 1993 (Miller et al., , 1995 . The inhibition of BCR signaling by LMP2A correlates with lower levels of EBV lytic replication, which has implicated LMP2A as a critical mediator of viral latency (Miller et al., 1994) . One mechanism by which LMP2A interferes with BCR signaling is thought to be through its constitutive association with the tyrosine kinases Lyn and Syk (Burkhardt et al., 1992) , thereby inhibiting their recruitment to the BCR upon activation. In this report, we observed equivalent levels of tyrosine phosphorylation in B cells from non-transgenic and LMP2A Tg6 transgenic mice following BCR activation. In primary murine splenic B cells, LMP2A is expressed at much lower levels than in established, EBV-transformed human lymphoblastoid cell lines (LCLs), which may explain the differences observed in phosphotyrosine induction . One might predict that the repression in gene transcription that was observed following BCR activation of B cells from LMP2A Tg6 mice is consistent with the potential transcriptional effects of BCR activation in the presence of a constitutive, basal signal provided by LMP2A in human cell lines in vitro. Furthermore, apparently normal induction of tyrosine phosphorylation in the presence of transcriptional alterations suggests that LMP2A does not block BCR signaling, rather somehow alters normal signal transduction pathways in order to repress downstream gene transcription. Altered BCR signaling might then allow for the survival of latently infected B cells in the absence of classical BCR activation, which would induce lytic replication.
It remains to be determined exactly how altered BCR signaling and transcriptional regulation by LMP2A affects normal B-cell function. Because we chose to simplify the transcriptional analysis by measuring gene expression at one time-point, 5 h after BCR activation, it is possible that we were unable to detect additional changes in short-lived, early gene induction following Ig treatment. Additionally, we cannot rule out the possibility that LMP2A mediates a delay in normal transcriptional induction or down-regulation following BCR activation, which might be observed at a later time point. However, our results indicate that LMP2A alters normal gene transcription in some manner, whether by complete repression or delayed expression, which may contribute to the maintenance of EBV latency. It is interesting to note that many genes that were not induced following BCR stimulation in LMP2A Tg6 B cells when compared to wild-type B cells included those involved in protein transport and sorting, cell -cell interactions, and inflammation and immunity. This may highlight an important role for LMP2A in regulating or modulating specific B-cell functions, thereby allowing EBV to persist during latency. In addition, genes that were induced in LMP2A Tg6 B cells when compared to wild-type B cells included genes encoding transcription factors, involved in DNA/RNA metabolism, and associated with cell cycle/apoptosis. These observations may also indicate an essential role for LMP2A in vivo, insuring that latently infected cells are resistant to apoptosis or other stimuli that may detrimentally affect the survival of EBV-infected cells in the human host.
In summary, we have compared gene expression in B cells from wild-type versus LMP2A Tg6 transgenic mice following BCR activation. We demonstrated that, before BCR activation, the transcriptional profile of B cells from LMP2A Tg6 mice was similar to that of wild-type mice. However, upon BCR activation, LMP2A appeared to repress both the induction and down-regulation of many genes that share common functions and are likely to be important for normal B-cell activation. Furthermore, BCR activation of B cells from LMP2A Tg6 transgenic mice resulted in increased expression of genes encoding transcription factors and regulators of DNA/RNA metabolism, which may be responsible for alterations in gene transcription following BCR activation. Future studies utilizing this mouse model to address the exact mechanisms by which LMP2A alters signaling and gene expression following BCR activation may provide better insight into the ways in which LMP2A promotes latency in EBV-infected B lymphocytes.
Materials and methods
Isolation of primary B cells from mice
Construction and characterization of the EA Tg6 LMP2A transgenic mice have been described previously . All animals were housed at the Northwestern University Center for Experimental Animal Resources in accordance with university animal welfare guidelines. To isolate primary B cells, spleens were dissociated between frosted slides in RPMI to prepare single cell suspensions. Red blood cells were lysed and B cells were negatively selected on magnetic cell sorting (MACS) columns utilizing magnetic beads coated with CD43 antibodies (Miltenyi Biotec, Auburn, CA). B cells were tested for purity by FACS analysis and cells shown to be >95% CD19+ B cells by flow cytometry were utilized for microarray analyses. B cells were placed at 10 Â 10 6 cells/ml in 2 ml of RPMI 1640 medium supplemented with 10% fetal bovine serum (FBS), 1000 U/ml penicillin, and 1000 Ag/ml streptomycin. Cells were either left untreated or treated with 25 Ag goat anti-mouse Ig (H + L) (Southern Biotechnology, Birmingham, AL) for a total of 5 h at which time RNA was isolated. After 5 min of antibody treatment, 5 Â 10 6 cells were removed for isolation of protein for Western blots.
Protein isolation and Western blots
B cells (5 Â 10 6 ) were lysed in buffer containing 125 mM HEPES, pH 7.5, 750 mM NaCl, 50 mM MgCl 2 , 5 mM EDTA, 10% glycerol, 10 Ag/ml aprotinin, 10 Ag/ml leupeptin, 25 mM NaF, and 1 mM sodium orthovanadate. Protein levels were measured by Bradford assay (BioRad, Hercules, CA) and equivalent amounts of protein were subjected to heat denaturation at 70 jC for 10 min. Samples were run on 4-15% SDS-PAGE gels (Bio-Rad) at 100 V for 1.5 h and transferred to Immobilon-P membranes (Millipore, Bedford, MA). Recombinant antiphosphotyrosine, RC20, conjugated to horseradish per-oxidase (Transduction Laboratories, Lexington, KY) was diluted 1:2000 in TBST (150 mM NaCl, 50 mM TrisCl, pH 8, and 0.05% Tween 20) supplemented with 5% BSA and utilized to detect tyrosine phosphorylation, followed by ECL detection (Amersham Pharmacia Biotech, Piscataway, NJ) and autoradiography.
RNA preparation and microarray experiments
Total RNA was extracted from B cells according to the Trizol reagent protocol (Invitrogen, Carlsbad, CA). RNA was then subjected to cleanup using the Qiagen Rneasy Mini Kit according to the RNA cleanup protocol (Qiagen, Valencia, CA). Aliquots of RNA were then removed and run on 1% agarose/formaldehyde gels to verify that no degradation occurred. Additionally, OD readings were taken and 20 Ag of total RNA having OD A 260 /A 280 readings between 1.9 and 2.1 was utilized for reverse transcription. Doublestranded cDNA was then generated according to the Superscript Double-Stranded cDNA Synthesis Kit (Invitrogen) using an oligo dT/T7 primer (5V -GGCCAGTGAATTGTAA-TACGACTCACTATAGGGAGGCGG-(dT) 24 -3V ). Following phenol/chloroform extraction and ethanol precipitation, cRNA was in vitro transcribed and labeled with biotin using the Enzo Bioarray RNA Transcription Labeling Kit (Affymetrix, Santa Clara, CA). The cRNA was purified using CHROMA SPIN 100 columns (Clontech, Palo Alto, CA) and ethanol precipitated. cRNA having OD A 260 /A 280 readings between 1.9 and 2.1 were again run on agarose/ formaldehyde gels to check for transcripts ranging between 35 and 200 bases and 20 Ag of these products was fragmented in fragmentation buffer containing 200 mM Tris-acetate, pH 8.1, 500 mM KOAc, and 150 mM MgOAc, at 95 jC for 35 min. Fragmented, biotinylated cRNA was then submitted for hybridization by the Children's Memorial Institute for Education and Research (CMIER) microarray facility at Northwestern University. The murine genome U74A chips were purchased from Affymetrix and utilized for analysis.
Statistical significance of differential expression
The Affymetrix system of expression quantification using perfect and mismatched oligonucleotides was used in conjunction with the system of background detection. At least two separate, identical experiments comparing gene transcription in untreated and BCR-activated B cells from LMP2A transgenic mice and non-transgenic littermates were performed. The entire data set for these experiments is available at http://bugs.mimnet.northwestern.edu/mimweb/ microarray.htm. The GeneSpring data analysis program (Silicon Genetics, Redwood City, CA) was utilized to generate scatter plots for overall expression comparisons. A t-distribution was applied to the differences in gene expression between BCR activation in B cells from wildtype versus LMP2A Tg6 transgenic mice. Genes with changes in differential expression values of twofold or greater, probability values less than 0.05, and Affymetrix calls other than no change were considered statistically significant.
